Lymphangioleiomyomatosis

This is a rare lung disease where smooth muscle cells grow into the lymphatic vessels. It mainly affects women and can cause breathing problems.

Condition

What people with Lymphangioleiomyomatosis report

Every report comes from a Lived member, sent anonymously.

Have you tried Sirolimus for Lymphangioleiomyomatosis?

NameHow it went

About Lymphangioleiomyomatosis

What It Is

Lymphangioleiomyomatosis (LAM) is a rare, slowly progressive disease in which abnormal cells resembling smooth muscle grow in the lungs and in the lymphatic system, the network of vessels that drains fluid from body tissues. In the lungs, these LAM cells gradually break down healthy tissue and leave many small, thin-walled air pockets called cysts. As cysts accumulate, breathing becomes less efficient and less oxygen reaches the blood. LAM affects almost only women, and symptoms usually begin between about 20 and 40. The most common early problems are shortness of breath that first appears with exertion and a collapsed lung (pneumothorax), which often happens more than once. LAM can also cause fluid to collect around the lungs or in the abdomen, and benign kidney tumors called angiomyolipomas. Because LAM cells can travel through the body, specialists classify LAM as a low-grade tumor that can spread, although it typically develops over years rather than months. There are two forms. Sporadic LAM appears on its own. The other form occurs in people with tuberous sclerosis complex (TSC), an inherited condition that causes noncancerous growths in many organs, and is called TSC-LAM.

Causes & Risk Factors

LAM is caused by changes in one of two genes, TSC1 or TSC2. These genes normally act as a brake on cell growth by restraining a signaling pathway called mTOR. When a cell loses both working copies of one of these genes, the brake fails, and LAM cells grow and spread. In TSC-LAM, one faulty copy is inherited and present in every cell. Between a quarter and a half of women with TSC develop LAM, and the proportion rises with age. Men with TSC can have lung cysts too, but these rarely cause symptoms. In sporadic LAM, the gene changes arise during life rather than being inherited, so sporadic LAM is not passed to children and there is usually no family history. Estrogen appears to drive the disease. LAM cells carry estrogen receptors, LAM mainly affects women between puberty and menopause, and pregnancy, estrogen-containing medicines and fertility treatment have been linked to its onset or worsening. Lung function decline often slows after menopause. There is no known way to prevent LAM.

How It's Diagnosed

LAM is often missed at first. Its breathlessness and wheezing resemble asthma or chronic obstructive pulmonary disease (COPD), and an ordinary chest X-ray can look normal early on, so diagnosis takes three to five years on average from the first symptoms. A collapsed lung, or cysts noticed on a scan done for another reason, often prompts the right tests. The key test is a high-resolution computed tomography (CT) scan of the chest, which shows many round, thin-walled cysts spread evenly through both lungs. Several other diseases also cause lung cysts, so the CT pattern alone is not enough. The diagnosis is usually confirmed when the typical scan comes with another sign of LAM: tuberous sclerosis complex, a kidney angiomyolipoma, a fluid-filled lymphatic growth in the abdomen or pelvis (lymphangioleiomyoma), or a high blood level of VEGF-D (vascular endothelial growth factor D), a protein made by LAM cells. A VEGF-D level above 800 pg/mL (picograms per milliliter) in someone with typical cysts is close to definitive and can spare them a biopsy, but a normal level does not rule LAM out. When none of these confirming signs is present, a lung biopsy may be needed. Breathing tests show how much the disease affects the lungs and set a baseline for follow-up. The most important number is FEV1 (forced expiratory volume in one second), the volume of air a person can blow out in one second, reported as a percentage of the value expected for someone of the same age, height and sex. Lung function is normal in up to half of people at diagnosis. A test of how well the lungs transfer oxygen into the blood, a six-minute walking test that tracks oxygen levels, and imaging of the abdomen to look for kidney growths are also typical parts of the assessment.

Treatment Options

There is no cure for LAM, but treatment can slow or halt the loss of lung function, shrink growths elsewhere in the body and manage complications. Sirolimus (Rapamune) is the main treatment and the only medicine approved by the Food and Drug Administration (FDA) for LAM. It is an mTOR inhibitor: it puts back part of the growth brake that the faulty genes removed. In the key clinical trial, people with moderately reduced lung function lost about 12 milliliters of FEV1 a month on placebo, while their lung function held steady on sirolimus. Sirolimus generally stabilizes rather than restores lung function, and the benefit lasts only while it is taken: when the trial stopped the drug, decline resumed. Specialists usually recommend it when lung function is reduced or falling quickly, when oxygen levels are low, or for kidney angiomyolipomas 4 centimeters or larger and troublesome lymphatic fluid collections. It may also be considered after repeated collapsed lungs. Everolimus, a closely related drug, is sometimes used instead. Sirolimus also suppresses the immune system, so it raises the risk of infections, and live vaccines should be avoided while taking it. Common side effects include mouth sores, diarrhea, nausea, an acne-like rash, leg swelling and higher cholesterol, mostly in the first months. Regular blood tests check the drug level along with blood counts, kidney and liver function, cholesterol and blood sugar. Other care targets specific problems. Inhalers that open the airways (bronchodilators) help some people who wheeze. A collapsed lung is usually treated with a chest tube, and because collapse tends to recur, doctors often recommend pleurodesis after the first episode, a procedure that seals the lung to the chest wall. Pulmonary rehabilitation, a supervised exercise and education program, improves exercise capacity. Oxygen is added when blood oxygen levels fall. A lung transplant is an option for advanced disease, and people with LAM do as well after transplant as people with other lung diseases, or better. Treatments aimed at hormones, such as estrogen-blocking drugs or removal of the ovaries, have not proven helpful and are not recommended. Estrogen-containing birth control, hormone replacement therapy and fertility treatment should be avoided because they can worsen LAM. Copper or progestin intrauterine devices, progestin implants, barrier methods and partner vasectomy are among the alternatives for contraception.

What to Expect

LAM usually progresses slowly, but the pace varies widely. Some people have few symptoms for many years, while others lose lung function faster and eventually need oxygen. The outlook has improved considerably: studies in the United States report transplant-free survival of more than 20 years. Lung function decline also tends to slow after menopause. Daily life often involves matching activity to breathing capacity. Regular physical activity is encouraged for most people, and studies of supervised exercise have not found a higher risk of collapsed lung. Flying and travel to high altitude need a conversation with the specialist, particularly for people with extensive cysts, poor lung function or past collapsed lungs, and scuba diving is generally avoided. Bone thinning is common, so bone density checks are part of routine care. Follow-up typically means visits every three to six months in the first year and every six to twelve months once the disease is stable, with breathing tests at most visits, a chest CT every few years and abdominal imaging to watch kidney growths. Because LAM is rare, care at a center experienced with it is valuable. Pregnancy is possible, but rising hormone levels can accelerate LAM and raise the risk of collapsed lung, fluid around the lungs and preterm birth. Sirolimus is usually stopped at least three months before conception. Women with stable, near-normal lung function often have uncomplicated pregnancies, and the decision is best planned in advance with the specialist. Living with an unpredictable rare disease can also affect mood, and counseling and patient support groups can help.

When to Seek Help

See a doctor, ideally a lung specialist, about breathlessness that is gradually worsening, wheezing that does not respond to asthma treatment, or a collapsed lung without an obvious cause, particularly if you are a woman between puberty and menopause or have tuberous sclerosis complex. If you have LAM, contact your care team promptly about coughing up blood, milky fluid in sputum or urine, new swelling of the abdomen or legs, or fever and other signs of infection while taking sirolimus. Sudden chest pain with shortness of breath can mean a collapsed lung and needs emergency care. Sudden severe pain in the side, back or abdomen, especially with feeling faint, can signal bleeding from a kidney angiomyolipoma and also needs emergency care.

Questions to Ask Your Doctor

  1. 1.Is my LAM sporadic or linked to tuberous sclerosis complex, and what does that mean for me and my family?
  2. 2.Based on my breathing tests, should I start sirolimus now, and how will we judge whether it is working?
  3. 3.If my lung collapses, what should I do, and should I have a procedure to prevent it from happening again?
  4. 4.Which birth control methods are safe for me, and how would LAM and its treatment affect a pregnancy?
  5. 5.Is it safe for me to fly, travel to high altitude or exercise hard?

Last reviewed • Oct 2026

Educational content, not medical advice.